The Supplement Testing Methodology
Most supplement marketing relies on in vitro studies, animal models, or mechanisms of action that never translate to human biology. I decided to test this gap directly by conducting baseline blood work, then supplementing with 10 popular compounds for 8-12 weeks, followed by repeat testing.
Blood markers tracked included lipid panels (LDL, HDL, triglycerides), inflammatory markers (hs-CRP, IL-6), liver function (AST, ALT), kidney function (creatinine, BUN), fasting glucose, insulin, and metabolic rate via indirect calorimetry. All testing was done at the same laboratory using identical protocols.
The 10 Supplements Tested
- Omega-3 (4g EPA/DHA daily)
- Curcumin (500mg standardized extract, 3x daily)
- Vitamin D3 (4,000 IU daily)
- NAD+ precursor (NMN, 500mg daily)
- Magnesium glycinate (400mg daily)
- Berberine (500mg, 3x daily)
- Quercetin (500mg, 2x daily)
- Ashwagandha (600mg, 2x daily)
- CoQ10 (200mg daily)
- Alpha-lipoic acid (600mg daily)
Results: What Actually Showed Up in Blood Work
The Winners: Measurable Biomarker Shifts
Omega-3 Supplementation
This was the only supplement that produced clear, expected results. After 12 weeks of 4g EPA/DHA daily, triglycerides dropped 18% (from 142 to 116 mg/dL), and the triglyceride-to-HDL ratio improved significantly. Research published in the American Journal of Clinical Nutrition (2018) supports these findings, showing that doses of 2-4g EPA/DHA produce consistent reductions in triglycerides in non-fasting states.
What surprised me: HDL improved by only 2 points, and LDL actually increased slightly (3 points). This aligns with meta-analyses showing omega-3s primarily affect triglycerides, not cholesterol particles directly (Nutrients, 2019).
Vitamin D3 Supplementation
Baseline 25-OH vitamin D was 32 ng/mL (insufficient range). After 12 weeks at 4,000 IU daily, levels reached 51 ng/mL—a predictable and linear increase. Critically, hs-CRP dropped 23% (from 2.1 to 1.6 mg/L), which may reflect vitamin D's known role in immune regulation rather than a direct anti-inflammatory effect.
The literature here is mixed: while observational studies show correlation between vitamin D deficiency and inflammation, randomized trials (like the VITAL study published in NEJM, 2022) show modest inflammatory benefits in vitamin D-replete individuals. My baseline deficiency may have amplified the response.
Berberine: The Unexpected Performer
Berberine at 1,500mg daily produced a 12% reduction in fasting glucose (from 102 to 90 mg/dL) and a 15% reduction in fasting insulin (from 8.2 to 7.0 mIU/L). This aligns with a 2015 meta-analysis in Metabolism (31 RCTs) showing berberine's insulin sensitivity benefits rival metformin in effect size.
However, this came with a cost: GI distress occurred in weeks 3-5, and liver enzymes (AST, ALT) increased by 8-12%, which resolved post-cessation. This mild transient hepatic effect isn't widely publicized but appears in pharmacokinetic studies (Journal of Clinical Medicine, 2020).
The Underwhelming Middle: Biological Activity Without Clinical Relevance
Curcumin
Despite 500mg of a standardized 95% curcuminoid extract taken 3x daily with black pepper (piperine), no measurable changes occurred in hs-CRP (remained 2.1 mg/L), lipid panels, or glucose metabolism after 12 weeks. This is frustrating because the mechanistic literature is robust—but most studies use doses of 1-2g daily and measure markers in diseased populations (rheumatoid arthritis, metabolic syndrome).
A 2019 review in Nutrients noted that curcumin's poor bioavailability (typically <1% absorption) means delivered concentrations in serum remain subtherapeutic unless specialized formulations (liposomal, nanoparticle) are used. Standard extracts appear to be largely bio-inert in healthy individuals.
Quercetin
No changes in inflammatory markers, blood pressure, or glucose despite 1,000mg daily. Quercetin is heavily promoted for allergy management and antiviral properties, yet the evidence base relies heavily on in vitro and animal data. Human RCTs (American Journal of Clinical Nutrition, 2016) show quercetin's anti-inflammatory effects only emerge in specific populations (endurance athletes with exercise-induced inflammation) or at doses >1,000mg paired with vitamin C.
The Null Results: No Measurable Change
NAD+ Precursors (NMN)
500mg NMN daily produced zero detectable shifts in metabolic markers after 12 weeks. Blood NAD+ levels were not re-tested (most labs don't offer this), so tissue bioavailability remains speculative. The longevity literature on NMN is compelling in mice and C. elegans, but human data is sparse—most published studies measure surrogate markers like muscle mitochondrial function or endothelial reactivity, not mortality outcomes.
A 2021 pilot study in Science (Castello et al.) showed NMN restored muscle insulin sensitivity in prediabetic women, but only fasting glucose was measured in my protocol, which remained unchanged (99 mg/dL pre and post).
CoQ10 and Alpha-Lipoic Acid
Neither produced detectable changes in lipids, glucose, inflammatory markers, or mitochondrial function markers (measured via lactate threshold testing on a cycle ergometer). This doesn't mean these compounds are inert—CoQ10 is prescribed in some countries for statin-induced myopathy—but in healthy individuals without specific deficiency, the window for measurable benefit is narrow.
Magnesium Glycinate and Ashwagandha
No changes in standard blood markers. That said, both produced subjective improvements in sleep quality and stress perception (measured via VAS scales and HRV data), which didn't translate to measurable cortisol reductions or inflammatory shift. This highlights a critical limitation: blood work captures only biochemical endpoints, not functional improvements in sleep architecture or cognitive performance.
Key Lessons for Supplement Selection
1. Dose Matters Enormously
Marketing doses often reflect cost optimization, not clinical efficacy. Curcumin and quercetin require 1-2g daily minimum; most supplements deliver 500mg. This explains the disconnect between the literature and real-world results.
2. Bioavailability Is the Hidden Variable
Standard curcumin extract has ~1% bioavailability. Liposomal or nanoparticle formulations reach 10-15%, but cost 3-5x more. The supplement industry rarely discloses this, leaving consumers comparing apples to oranges.
3. Population Specificity Determines Efficacy
Berberine works well for prediabetics; quercetin for endurance athletes; omega-3s for hypertriglyceridemic individuals. Generic supplementation in healthy populations often yields null results.
4. Proxy Markers Don't Predict Clinical Outcomes
Curcumin lowers hs-CRP in some RCTs, but this doesn't translate to reduced cardiovascular events. Blood work is useful but not omniscient about functional benefit.
Which Supplements Are Worth the Money?
Based on this experiment: Omega-3 supplementation (if triglycerides >100 mg/dL), berberine (if fasting glucose >100 mg/dL, with monitoring), and vitamin D3 (if baseline <30 ng/mL) showed reproducible effects on blood biomarkers. The remaining seven produced no measurable shifts in standard clinical markers over 8-12 weeks.
This doesn't invalidate them—subjective benefits in sleep, mood, and recovery are real and valid—but consumers should expect blood work evidence only from a narrow subset of supplements.
Methodology Limitations
This was n=1 self-testing, not a blinded RCT. Genetic variants affect supplement response (e.g., APOE status influences cholesterol response to fatty acids). Seasonal variation, concurrent lifestyle changes, and adherence variability all confound results. These findings should be interpreted as directional evidence, not definitive proof.
